Based on clinical cohorts, it has been found that carrying the COX-2 Val511Ala SNP is not associated with a risk of CRC, and that the use of NASID in combination can help reduce the risk of CRC in African Americans 100. The gene discussed is PTGS2; the disease is colorectal carcinoma.